JiangSu DaLong Pharmaceutical Technology Co., Ltd signed the Provincial Distribution Agreement for "Shenge Bushen Capsule" with Huachun Biological Pharmaceutical Co., Ltd
August 24th 2023, Mr. Zhang Yongchang from JiangSu DaLong Pharmaceutical Technology Co., Ltd and Mr. Li Chenggong, Chairman and President of the Board of Directors of Huachun Investment Group and Chairman of Huachun Biological Pharmaceutical Co., Ltd signed the "Shenge Bushen Capsule" Promotion Service Agreement and Provincial General Distribution Agreement " in Urumqi.
Huachun Biological Pharmaceutical and the School of Life Sciences at Tsinghua University jointly developed and own the complete intellectual property of the innovative Class 1.1 newly-developed Chinese antidepressant, "Shenge Bushen Capsule". It is not only the first traditional Chinese patent medicine and simple preparations in the world to treat depression with the combination of effective parts, but also the first 13th Five Year Plan "National Major New Drug Development ? Major Science and Technology Special Project" (project number: 2018ZX09731020) medicine for the treatment of mild to moderate depression in China. It is the only Class 1.1 newly-developed drug of traditional Chinese medicine that the Center For Drug Evaluation, NMPA approved in 2022 as well.
